HeartWare International (NASDAQ: HTWR) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare HeartWare International to similar companies based on the strength of its risk, earnings, valuation, analyst recommendations, institutional ownership, dividends and profitability.
This is a breakdown of current ratings and price targets for HeartWare International and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|HeartWare International Competitors||127||739||1041||10||2.49|
Institutional and Insider Ownership
54.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares HeartWare International and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|HeartWare International Competitors||-100.14%||-92.44%||-29.75%|
Valuation & Earnings
This table compares HeartWare International and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|HeartWare International Competitors||$1.67 billion||$207.76 million||56.39|
HeartWare International’s peers have higher revenue and earnings than HeartWare International. HeartWare International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
HeartWare International peers beat HeartWare International on 5 of the 8 factors compared.
About HeartWare International
Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. It develops MVAD System, a miniaturized device. The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass.
Receive News & Ratings for HeartWare International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International and related companies with MarketBeat.com's FREE daily email newsletter.